You searched for "Myeloma" from the Body Image.

Stage	Phase	Principal Investigator	Study prefix	Study number	Title (click hyperlink for more information)
	I	Asher Chanan Khan, MD	PH	124307	(MDX1342-02) A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients with CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia
First Line Therapy	I/II	Asher Chanan Khan, MD	RPC	01-12	A Phase I/II Study of Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL)
	I/II	Asher Chanan Khan, MD	PH	144008	(A5481004-1008) Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma
	I	Asher Chanan Khan, MD	PH	147608	(C14003) Phase I Trial of MLN8237 a novel Arora Kinase Inhibitor in Patients with Hematologic Malignancy
	I/II	Asher Chanan Khan, MD	PH	129108	(HuLuc63-1702) A Phase 1/2, Multi-Center, Open-Label, Dose-Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal IgG1 antibody) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies
Relapsed or Refractory	I	Asher Chanan Khan, MD	PH	51805	A Phase I Study to Assess the Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma
	I	Asher Chanan Khan, MD	I	132608	Phase I Dose Escalation to Evaluate Maximum Tolerated Dose (MTD), Pharmacokinetics (PK) and Safety of BT062 in Subjects with Relapsed or Relapsed/Refractory Multiple Myeloma
	III	Asher Chanan Khan, MD	NCG	142908	(E1A06) An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid TM) (MPR) in Newly Diagnosed Mulitple Myeloma Patients Who Are Not Candidates for High Dose Therapy

Total number of Clinical Trials found: 8

Return to Search page